Woodlands Medical Specialists, Pa

Pensacola, Florida 32503

1 studies enrolling now · 19 studies all time

What they study most

Breast Neoplasm, Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Disease Progression, Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN), Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Metastatic Breast Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Prostate Cancer

Studies at this site

• MYLUNG Consortium Part 3: Observational Study — Recruiting now
• Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread — Recruiting now
• Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) — Running, not enrolling
• A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) — Completed
• Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) — Completed
• MYLUNG Consortium Study Protocol 2 — Running, not enrolling
• Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) — Running, not enrolling
• A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment — Stopped early
• Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer — Running, not enrolling
• Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307) — Completed
• Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study — Stopped early
• Treatment Resistance Following Anti-cancer Therapies — Stopped early
• A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck — Stopped early
• Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART) — Status unconfirmed
• Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer — Stopped early
• A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer — Completed
• The Circulating Cell-free Genome Atlas Study — Status unconfirmed
• Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test Into Clinical Practice — Completed
• Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer — Completed